Loading
A phase 1/2 trial of Bexobrutideg, Venetoclax, Rituximab and Obinutuzumab in non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by Nurix Therapeutics, Inc., now recruiting.
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies is a phase 1/2 interventional study registered as NCT07520006 by Nurix Therapeutics, Inc., with 150 participants planned, started 2026-08 and due to reach its primary completion in 2033-05. Interventions recorded: NX-5948, venetoclax, rituximab and obinutuzumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bexobrutideg, Nurix Therapeutics, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Obinutuzumab, Venetoclax, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Venetoclax, Rituximab, Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Venetoclax, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Obinutuzumab, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/